⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

November 22, 2017Liver InternationalOpen Access

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Mukul R. Jain Suresh Giri Bibhuti Bhoi Chitrang Trivedi Akshyaya Rath Rohan Rathod Ramchandra Ranvir Shekhar Kadam Hiren Patel Prabodha Swain Sib Sankar Roy Nabanita Das Eshani Karmakar Walter Wahli Pankaj Patel

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Saroglitazar, a dual PPARα/γ agonist with predominant PPARα activity, shows an overall improvement in NASH. The effects of saroglitazar appear better than pure PPARα agonist, fenofibrate and PPARγ agonist pioglitazone.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jain et al. (2017) studied this question.

synapsesocial.com/papers/69d8462ca2a48916bbbefb5e https://doi.org/10.1111/liv.13634

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes StudyOriginal Research · 2011 · 393 citations
2Non-alcoholic fatty liver disease and diabetesBlinded Clinical Trial · 2016 · 528 citations
3Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)Clinical Trial · 2013 · 460 citations
4Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitisClinical Trial · 2010 · 1,077 citations
5Role of Mitochondria in Nonalcoholic Fatty Liver DiseaseReview · 2014 · 360 citations
6Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLDOriginal Research · 2016 · 746 citations
7Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver diseaseReview · 2014 · 1,578 citations
8Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension TrialRCT · 2009 · 363 citations
9TTK Promotes Hepatic Fibrosis Through PKM2 / H3T11 ‐Mediated GLS1 ‐Dependent Glutamine CatabolismLiver International · 2026
10Body Adiposity as a Risk Factor for Portal Vein Thrombosis in Patients With CirrhosisLiver International · 2026

More from Liver International

More from Nanyang Technological University

More from Indian Institute of Chemical Biology

More from Cadila Healthcare (India)